Depo-Provera is an injectable contraceptive containing medroxyprogesterone acetate, a synthetic form of the hormone progesterone. Administered every three months, this birth control method has been used by millions of women since its FDA approval. While effective for pregnancy prevention, growing evidence has linked prolonged Depo-Provera use to the development of meningiomas, tumors that form in the membranes surrounding the brain and spinal cord.
Multiple peer-reviewed studies have documented a significantly increased risk of meningioma development in long-term Depo-Provera users:
These findings represent a consistent pattern across independent research institutions, establishing a clear association between prolonged Depo-Provera use and meningioma risk.
Depo Provera lawsuits allege that Pfizer and Pharmacia & Upjohn failed to adequately warn users about the risks associated with long-term use of their contraceptive injection. Plaintiffs claim the companies knew or should have known about the connection between Depo-Provera and meningioma development but delayed informing the public.
Despite internal awareness of meningioma risks, Pfizer did not seek FDA approval for updated warning labels until February 2024. The FDA initially denied this request. Pfizer resubmitted with amendments in June 2025, and the FDA finally approved updated labeling on December 12, 2025, more than a year after the initial submission. These lawsuits assert that Pfizer prioritized profits over patient safety by continuing to sell the contraceptive without proper warnings to American consumers for years after the risks became known.
Meanwhile, Pfizer had already updated warning labels in Canada, the UK, and Europe prior to the FDA’s December 2025 approval, creating a disparity in how different patient populations were informed about meningioma risks.
By filing a Depo Provera lawsuit, you may be eligible to seek compensation for medical expenses, surgical costs, pain and suffering, lost wages, and other damages resulting from meningioma development linked to Depo-Provera use. These legal actions aim to hold Pfizer accountable for potentially putting patients at risk and to ensure that pharmaceutical manufacturers prioritize user safety.
If you or a loved one received Depo-Provera injections and have been diagnosed with a meningioma, contact our legal team to understand your rights and potential eligibility for compensation.
The Depo-Provera MDL in the Northern District of Florida now includes over 2,200 active pending lawsuits, with new cases filed regularly.
The FDA approved updated Depo-Provera labeling to include meningioma warnings. The MDL case count continued to grow.
A Cleveland Clinic study published in JAMA Neurology further validated claims about long-term use risks. The MDL exceeded 800 lawsuits. Oral arguments on Pfizer’s preemption motion were heard on September 29, 2025.
Judge Rodgers scheduled oral arguments on Pfizer’s federal preemption motion for September 29, 2025.
The MDL grew to approximately 348 active cases as awareness of the litigation expanded.
Discovery officially opened with an aggressive scheduling order. BrownGreer was appointed as Data Administrator, and plaintiffs began submitting proof of Depo-Provera use and meningioma diagnoses.
The Depo-Provera MDL (3140) was formally established and centralized in the Northern District of Florida under Judge M. Casey Rodgers. Early filings already numbered in the hundreds as plaintiffs came forward with meningioma diagnoses.
